Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Afsaneh Asgharian"'
Publikováno v:
Western Journal of Emergency Medicine, Vol 24, Iss 3 (2023)
Introduction: Emergency department (ED) utilization for psychiatric disease is increasing, and a lack of health insurance has been identified as a potential cause of preventable or avoidable ED use. Through the Affordable Care Act (ACA), more uninsur
Externí odkaz:
https://doaj.org/article/48415b791c354967b264a707b09d3d6c
Autor:
Afsaneh Asgharian, Susan VanMeter, Soraya Shaikh, Jeffrey Ellis, Teri Jimenez, Clare W. Makumi
Publikováno v:
International Journal of Neuroscience. 126:30-38
Long-term safety of once-daily ropinirole extended/prolonged release (ropinirole XL/PR) was evaluated in subjects with early and advanced Parkinson's disease (PD) in this study, 101468/248. Subjects (n = 419) who completed one of three prior studies
Autor:
Birgit Högl, Christina Hill-Zabala, Afsaneh Asgharian, Luigi Ferini-Strambi, Diego Garcia-Borreguero, Richard P. Allen, John W. Winkelman
Publikováno v:
Movement Disorders. 27:277-283
The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS). Augmentation is the main complication of long-term dopaminergic treatment of RLS
Publikováno v:
Clinical Neuropharmacology. 31:281-286
OBJECTIVES To investigate the effect of twice-daily ropinirole in patients with early evening restless legs syndrome (RLS) symptoms, particularly focusing on the relationship of patient- and physician-rated assessment of treatment outcomes. METHODS I
Autor:
Louis Claybon, Afsaneh Asgharian, George W. Rung, Mark A. Kallgren, Chandra Patel, Judy Bryson, James Koppel, Allen H. Hord, Costantino Benedetti, Mary R. Creed
Publikováno v:
Anesthesia & Analgesia. 84:832-838
The use of opioids for postoperative analgesia may be limited by side effects such as nausea and vomiting. Because ondansetron, a selective serotonin type 3 (5-hydroxytryptamine [5-HT3]) antagonist, is effective for chemotherapy and general anesthesi
Publikováno v:
Clinical therapeutics. 35(9)
Background As with studies of other dopamine agonists, previously reported studies of ropinirole in restless legs syndrome (RLS) recruited patients with baseline International Restless Legs Scale (IRLS) total scores ≥15. The reported pooled analyse
Autor:
Diego, García-Borreguero, Birgit, Högl, Luigi, Ferini-Strambi, John, Winkelman, Christina, Hill-Zabala, Afsaneh, Asgharian, Richard, Allen
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 27(2)
The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS). Augmentation is the main complication of long-term dopaminergic treatment of RLS
Autor:
Afsaneh Asgharian, Heinz Reichmann, Clare W. Makumi, Kenneth J. Shulman, Mark F. Lew, Robert A. Hauser
Publikováno v:
The International journal of neuroscience. 121(5)
Long-term safety and efficacy of once-daily ropinirole prolonged release (PR) were evaluated in subjects with early Parkinson's disease (PD). Subjects (n = 83) who completed one of two studies were enrolled in this open-label, multicenter, extension
Autor:
Afsaneh Asgharian, Jack G. Modell, Carol B. Rockett, Alok Krishen, Vicki J. Foster, Donna S. Wightman, Alan Metz, April E. Harriett, Norman E. Rosenthal
Publikováno v:
Biological psychiatry. 58(8)
Background Seasonal affective disorder (SAD) can cause significant distress and impairment. No antidepressant studies have previously attempted to prevent the onset of autumn-winter depression. Methods Three prospective, randomized, placebo-controlle
Autor:
Priti Jhingran, Mike Markowitz, Susan H. Gordon, Afsaneh Asgharian, Jean-Francois Ricci, Eric G. Carter
Publikováno v:
Gastroenterology. 120:A634-A634